Proton Therapy Trial Among Patients With Stage I NSCLC

Share this content:
Researchers are evaluating whether hypoIGRT is an effective treatment strategy for patients with stage I NSCLC who are not candidates for surgery.
Researchers are evaluating whether hypoIGRT is an effective treatment strategy for patients with stage I NSCLC who are not candidates for surgery.

Title: Hypofractionated, Image-Guided Radiation Therapy With Proton Therapy for Stage I Non-Small Cell Lung Cancer1

Principal Investigators: Bradford S Hoppe, MD, MPH, University of Florida Proton Therapy Institute

Description: For this non-randomized study (ClinicalTrials.gov Identifier: NCT00875901), researchers are evaluating whether photon radiation therapy — hypofractionated image guided radiation therapy (hypoIGRT) — is an effective treatment strategy for patients with stage I non-small cell lung cancer (NSCLC) who are not candidates for surgery.

This treatment method is typically completed within 2 to 3 weeks, while conventional radiotherapy requires 7 to 8 weeks of treatment.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters